Meeting
2024 ASCO Annual Meeting
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
Authors
Minal A. Barve
Mary Crowley Cancer Research, Dallas, TX
Minal A. Barve , Tanner Michael Johanns , Niharika B. Mettu , Seth D Rosen , William Jeffery Edenfield , Martin Gutierrez , Aime Giorlando , Thomas Schuetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT03881488
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2535)
DOI
10.1200/JCO.2024.42.16_suppl.2535
Abstract #
2535
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.
First Author: Benjamin Philip Levy
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2024 ASCO Annual Meeting
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
First Author: Melissa Lynne Johnson
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%.
First Author: Neil E. Faulkner